Business Context and Reporting Period
Rocket Pharmaceuticals, Inc. (Delaware) filed this Form 8-K on December 27, 2018, reporting events occurring on December 27-28, 2018. The Company is an emerging growth company.
Key Financial Metrics and Transaction Details
- Stock Repurchase: 100,000 shares repurchased for approximately $1.4 million at a weighted-average price of $13.93 per share.
- Private Placement: 100,000 shares sold to RTW Innovation Master Fund, Ltd. (an affiliate managed by Chairman Roderick Wong) at $13.93 per share plus transaction expenses.
- Net Impact: No change in total shares issued and outstanding; no material change in assets or liabilities.
- Liquidity and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes Versus Prior Period
The filing describes a specific capital transaction rather than a period-over-period financial performance comparison. The net effect of the simultaneous repurchase and issuance is neutral regarding share count and balance sheet totals.
Management Commentary and Rationale
Management executed these transactions to assist in placing shares with long-term investors who believe the stock is undervalued. The structure was necessitated by limitations on the affiliate's ability to purchase shares directly on the open market. The transactions were conducted in accordance with SEC Rule 10b-18 and as a private placement under Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Confirm the final closing date of the transactions (expected on or about December 31, 2018).
- Verify the exact amount of transaction expenses paid by the affiliate in addition to the $13.93 per share price.
- Review the Company's most recent 10-K or 10-Q for current cash balances and liquidity status, as this 8-K does not provide them.
- Check for any subsequent filings regarding the affiliate's holding period or lock-up agreements.